Source: Annual Congress 2009 - Aspects of clinical asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Redford, M. L. Zaremba, S. Ali, N. Shah, S. Reddy (Port Huron, United States Of America). Impediments to the start of omalizumab in a small pulmonary practice. Eur Respir J 2009; 34: Suppl. 53, 1974

Member's Comments

No comment yet.

Related content which might interest you: Barriers to the continued use of omalizumab in a small outpatient setting Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Reducing the use of inhaled corticosteroids in mild COPD patients treated in primary care by a training program in national guidelines and using a portable device to measure pulmonary function Source: Eur Respir J 2005; 26: Suppl. 49, 294s Year: 2005 Real-life experience with mepolizumab in the French early access program for severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Discontinuation of inhaled corticosteroid treatment in patients with COPD diagnosed in general practice Source: Eur Respir J 2002; 20: Suppl. 38, 212s Year: 2002 Challenges to compliance in new CPAP users Source: Annual Congress 2009 - Continuous positive airway pressure therapy in obstructive sleep apnoea Year: 2009 Effectiveness of pulmonary rehabilitation programs on persistent asthma. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Improving symptomology in COPD: which therapy would you choose, a brochodilator or pulmonary rehabilitation? Source: International Congress 2019 – Hot topics in pulmonary rehabilitation Year: 2019 COPD guides and inhaled corticosteroids. Is there an adequate use in primary care? Source: International Congress 2016 – Targeting care, pulmonary rehabilitation, management, and self-management of COPD exacerbations in primary care Year: 2016 Effects of pharmacist interventions to inhalation medication adherence and lung functions in COPD patients at one stop service clinic Source: International Congress 2014 – COPD exacerbations Year: 2014 Stepping-down inhaled corticosteroid therapy in stable asthma: a secondary care perspective Source: Eur Respir J 2005; 26: Suppl. 49, 277s Year: 2005 Omalizumab decreases medical resource utilisation in patients with severe allergic asthma in an Italian real-life setting Source: International Congress 2017 – Asthma management Year: 2017 Budesonide/formoterol for the treatment of COPD exacerbations in the primary healthcare setting Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Maintenance of long term benefits from an outpatient pulmonary rehabilitation programme in COPD Source: Annual Congress 2011 - Challenges in rehabilitation: some old dilemmas revisited with some solutions? Year: 2011 Patients with COPD prescribed inhaled corticosteroid in primary care – Time for re-assessment based on exacerbation rate and blood eosinophils? Source: Virtual Congress 2020 – Diagnosis and management of airways disease in primary care Year: 2020 Predicting physician decision to prescribe systemic corticosteroids following an exacerbation of airways disease Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 Physician assessment of asthma control in patients receiving omalizumab in a real-world setting Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Expanding the scope of pulmonary rehabilitation Source: Annual Congress 2005 - The ERS/ATS statements on pulmonary rehabilitation Year: 2005 Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting Source: International Congress 2017 – Asthma management Year: 2017 Antibiotic effectiveness to prevent new chronic obstructive pulmonary disease (COPD) exacerbations in current medical practice Source: Annual Congress 2009 - Functional insights into COPD Year: 2009